Phosphodiesterase 5 inhibitors for erectile dysfunction

Annals of Pharmacotherapy

Volumn 39, Issue 7-8, 2005, Pages 1286-1295

  Setter, Stephen M ^a   Iltz, Jason L ^a,b   Fincham, Jack E ^c   Campbell, R Keith ^a   Baker, Danial E ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

^b CENTER FOR HEALTH STUDIES   (United States)

^c UNIVERSITY OF GEORGIA   (United States)

Author keywords

Erectile dysfunction; Phosphodiesterase inhibitors; Sildenafil; Tadalafil; Vardenafil

Indexed keywords

AMIODARONE; AMITRIPTYLINE; DESIPRAMINE; DIGOXIN; DOXAZOSIN; DOXEPIN; FLECAINIDE; GABAPENTIN; IMIPRAMINE; IRBESARTAN; LAMOTRIGINE; LOSARTAN; METHYLDOPA; MEXILETINE; MIRTAZAPINE; NEFAZODONE; NORTRIPTYLINE; OXCARBAZEPINE; PHOSPHODIESTERASE V INHIBITOR; PRAZOSIN; PROTRIPTYLINE; SILDENAFIL; TADALAFIL; TERAZOSIN; TOPIRAMATE; TRAZODONE; UNINDEXED DRUG; VARDENAFIL; VENLAFAXINE; ZONISAMIDE;

BACKACHE; CLINICAL TRIAL; DRUG ACTIVITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DYSPEPSIA; ERECTILE DYSFUNCTION; FLUSHING; FOOD DRUG INTERACTION; HEADACHE; HUMAN; MEDICAL LITERATURE; MEDLINE; MYALGIA; NOSE CONGESTION; PRIORITY JOURNAL; REVIEW; RHINITIS; VISUAL DISORDER;

3',5'-CYCLIC-GMP PHOSPHODIESTERASE; CARBOLINES; CLINICAL TRIALS; DIABETES COMPLICATIONS; DRUG INTERACTIONS; HUMANS; IMIDAZOLES; IMPOTENCE; MALE; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; PIPERAZINES; POSTOPERATIVE COMPLICATIONS; PROSTATECTOMY; SULFONES; TRIAZINES;

EID: 21744461489     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1E487     Document Type: Review

References (75)

1. NIH Consensus Conference. Impotence: NIH Consensus Development Panel on Impotence. JAMA 1993;270:83-90.
2. Korenman SG. Epidemiology of erectile dysfunction. Endocrine 2004; 23:87-91.
3. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994;151:54-61.
4. Siegel T, Moul JW, Spevak M, Alvord WG, Costabile RA. The development of erectile dysfunction in men treated for prostate cancer. J Urol 2001;165:430-5.
5. Stock RG, Kao J, Stone NN. Penile erectile function after permanent radioactive seed implantation for treatment of prostate cancer. J Urol 2001; 165:436-9.
6. Feldman HA, Johannes CB, Derby CA, Kleinman KP, Mohr BA, Araujo AB, McKinlay JB. Erectile dysfunction and coronary risk factors: prospective results from the Massachusetts Male Aging Study. Prev Med 2000;30:328-38.
7. Goldstein I. The mutually reinforcing triad of depressive symptoms, cardiovascular disease, and erectile dysfunction. Am J Cardiol 2000;86: 41F-5F.
8. Kandeel FR, Koussa VK, Swerdloff RS. Male sexual function and its disorders: physiology, pathophysiology, clinical investigation, and treatment. Endocr Rev 2001;22:342-88.
9. Gresser U, Gleiter CH. Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil: review of the literature. Eur J Med Res 2002;7:435-46.
10. Finger WW, Lund M, Slagle MA. Medications that may contribute to sexual disorders. A guide to assessment and treatment in family practice. J Fam Pract 1997;44:33-43.
11. Brock GB, Lue TF. Drug-induced male sexual dysfunction: an update. Drug Saf 1993;8:414-26.
12. Bansal S. Sexual dysfunction in hypertensive men: a critical review of the literature. Hypertension 1988;12:1-10.
13. Burnham TH, Wickersham RM, Novak KK, eds. Drug facts and comparisons. St. Louis, MO: Facts and Comparisons, 2004.
14. Prisant LM, Carr AA, Bottini PB, Solursh DS, Solursh LP. Sexual dysfunction with antihypertensive drugs. Arch Intern Med 1994;154:730-6.
15. Barksdale JD, Gardner SF. The impact of first-line antihypertensive drugs on erectile dysfunction. Pharmacotherapy 1999;19:573-81.
16. Mitchell JE, Popkin MK. Antidepressant drug therapy and sexual dysfunction in men: a review. J Clin Psychopharmacol 1983;3:76-9.
17. Mitchell JE, Popkin MK. Antipsychotic drug therapy and sexual dysfunction in men. Am J Psychiatry 1982;139:633-7.
18. Clayton AH, Pradko JF, Croft HA, Montano CB, Leadbetter RA, Bolden-Watson C, et al. Prevalence of sexual dysfunction among newer antidepressants. J Clin Psychiatry 2002;63:357-366.
19. Fava M, Rankin M. Sexual functioning and SSRIs. J Clin Psychiatry 2002;63(suppl 5):13-6.
20. Kennedy SH, McCann SM, Masellis M, McIntyre RS, Raskin J, McKay G, et al. Combining bupropion SR with venlafaxine, paroxetine, or fluoxetine: a preliminary report on pharmacokinetic, therapeutic, and sexual dysfunction effects. J Clin Psychiatry 2002;63:181-6.
21. Rosen RC, Kostis JB. Overview of phosphodiesterase 5 inhibition in erectile dysfunction. Am J Cardiol 2003;92(suppl):9M-18M.
22. Crowe SM, Streetman DF. Vardenafil treatment for erectile dysfunction. Ann Pharmacother 2004;38:77-85. DOI 10.1345/aph.1D019
23. Boolell M, Allen MJ, Ballard SA, Gepi-Attee S, Muirhead GJ, Naylor AM, et al. Sildenafil: an orally active type 5 cyclic GMP-speciflc phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Im J Impot Res 1996;8:47-52.
24. Meuleman E. Review of tadalafil in the treatment of erectile dysfunction. Exp Opin Pharmacother 2003;4:2049-56.
25. Fazio L, Brock G. Erectile dysfunction: management update. CMAJ 2004;170:1429-37.
26. Carrier S. Pharmacology of phosphodiesterase 5 inhibitors. Can J Urol 2003;10(suppl 1):12-6.
27. Kalsi JS, Bahadur G, Muneer A, Ozturk O, Christopher N, Ralph DJ, et al. Novel PDE5 inhibitors for the treatment of male erectile dysfunction. Reproductive Biomedicine Online 2003;7:456-61.
28. Viagra (sildenafil citrate) prescribing information. www/viagra.com/ professional/pi/proPacklnsert.asp (accessed 2004 May 26).
29. Levitra (vardenafil HCL) tablets: prescribing information. www.levitra.com (accessed 2004 May 26).
30. Cialis (tadalafil) prescribing information, www.cialis.com (accessed 2004 May 26).
31. Cheitlin MD, Hutter AM, Brindis RG, Ganz P, Kaul S, Russell ROJ, et al. ACC/AHA expert consensus document. Use of sildenafil (Viagra) in patients with cardiovascular disease. American College of Cardiology/ American Heart Association. J Am Coll Cardiol 1999;33:273-82.
32. Rearing GM, Scott LJ. Vardenafil: a review of its use in erectile dysfunction. Drugs 2003;63:2673-703.
33. Pomerol JM, Rabasseda X. Tadalafil, a further innovation in the treatment of sexual dysfunction. Drugs Today 2003;39:103-13.
34. Webb DJ, Muirhead GJ, Wulff M, JA Sutton JA, R. Levi R, Dinsmore WW. Sildenafil citrate potentiates the hypotensive effects of nitric oxide donor drugs in male patients with stable angina. J Am Coll Cardiol 2000;36:25-31.
35. Setter SM, Baker DE, Campbell RK, Johnson SB. Sildenafil (Viagra) for the treatment of erectile dysfunction. Diabetes Educator 1999;25:79-89.
36. Rosen RC, McKenna KE. PDE-5 inhibition and sexual response: pharmacological mechanisms and clinical outcomes. Annu Rev Sex Res 2002;3:36-88.
37. McDonald LJ, Murad F. Nitric oxide and cGMP signaling. Adv Pharmacol 1995;34:263-75.
38. Sussman DO. Pharmacokinetics, pharmacodynamics, and efficacy of phosphodiesterase type 5 inhibitors. J Am Osteopath Assoc 2004;104 (suppl 4):S11-5.
39. Pollack CV, Gibier BW. 2000 ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: a practical summary for emergency physicians. Ann Emerg Med 2001;38:229-40.
40. Rohde G, Wensing G, Unger S, Sachse R. The pharmacokinetics of vardenafil, a new selective PDE5 inhibitor, is minimally affected by coadministration with cimetidine or ranitidine (abstract). Pharmacotherapy 2001;21:1254.
41. Brock GB, McMahon CG, Chen KK, Costigan T, Shen W, Watkins V, et al. Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J Urol 2002;168:1332-6.
42. Streidle C, Feldman R, Letteiri J, et al. Pharmacokinetics of vardenafil (a new selective PDE5 inhibitor) in the elderly and subgroup data on efficacy and safety in elderly patients with erectile dysfunction (abstract). Presented at: Annual Meeting of the American Geriatrics Society, Chicago, May 9-13, 2001.
43. Steidle CP, Feldman R, Lettieri J, Agarwal V, Segerson T. Pharmacokinetics of vardenafil (a new selective PDE5 inhibitor) in the elderly and subgroup data on efficacy and safety in elderly patients with erectile dysfunction (abstract). J Am Geriatr Soc 2001;49:S103.
44. Pryor J. Vardenafil: update on clinical experience. Int J Impot Res 2002; 14(suppl 1):S65-9.
45. Brindis RG, Kloner RA. Sildenafil in patients with cardiovascular disease. Am J Cardiol 2003;92(suppl):26M-36M.
46. Kloner RA, Mitchell M, Emmick JT. Cardiovascular effects of tadalafil in patients on common antihypertensive therapies. Am J Cardiol 2003; 92(suppl):47M-57M.
47. Herschorn S. Cardiovascular safety of PDES inhibitors. Can J Urol 2003;10(suppl 1):23-8.
48. Kloner RA, Mitchell M, Emmick JT. Cardiovascular effects of tadalafil. Am J Cardiol 2003;92(suppl):37M-46M.
49. Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA. Oral sildenafil in the treatment of erectile dysfunction. New Eng J Med 1998;338:1397-404.
50. Padma-Nathan H, Steers WD, Wicker PA. Efficacy and safety of oral sildenafil in the treatment of erectile dysfunction: a double-blind, placebo-controlled study of 329 patients. Int J Clin Pract 1998;52:375-9.
51. Fagelman E, Fagelman A, Shabsigh R. Efficacy, safety, and use of sildenafil in urologic practice. Urology 2001;57:141-4.
52. Lewis R, Bennett CJ, Borkon WD, Boykin WH, Althof SE, Stecher VJ et al. Patient and partner satisfaction with Viagra (sildenafil citrate) treatment as determined by the erectile dysfunction inventory of treatment satisfaction questionnaire. Urology 2001;57:960-5.
53. Rendell MS, Rajfer J, Wicker PA, Smith MD. Sildenafil for treatment of erectile dysfunction in men with diabetes: a randomized controlled trial. Sildenafil Diabetes Study Group. JAMA 1999;281:421-6.
54. El-Sakka AI. Efficacy of sildenafil citrate in treatment of erectile dysfunction: effect of type 2 diabetes. Eur Urol 2004;46:503-9. DOI 10.1016/j.eururo.2004.06.005
55. Porst H, Rosen R, Padma-Nathan H, Goldstein I, Giuliano F, Ulbrich E, et al. The efficacy and tolerability of vardenafil, a new selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: the first at-home clinical trial. Int J Impot Res 2001;13:192-9.
56. Porst H, Young JM, Schmidt AC, Buvat J; Vardenafil Study Group. Efficacy and tolerability of vardenafil for treatment of erectile dysfunction in patient subgroups. Urology 2003;62:519-23.
57. Potempa A, Ulbrich E, Bernard I, Beneke M; Vardenafil Study Group. Efficacy of vardenafil in men with erectile dysfunction: a flexible-dose community practice study. European Urology 2004;46:73-9.
58. Hatzichristou D, Francesco F, Buvat J, Laferriere N, Bandel TJ, Porst H; European Vardenafil Study Group. The efficacy and safety of flexible-dose vardenafil (Levitra) in a broad population of European men. European Urology 2004;45:634-41.
59. Hellstrom WJG, Gittelman M, Karlin G, Segerson T, Thibonnier M, Taylor T, et al. Sustained efficacy and tolerability of vardenafil, a highly potent selective phosphodiesterase type 5 inhibitor, in men with erectile dysfunction: results of a randomized, double-blind, 26-week placebo-controlled pivotal trial. Urology 2003;61(suppl 1):8-14.
60. Rosen RC, Padma-Nathan H, Shabsigh R, Saikali K, Watkins V, Pullman WE. Cialis (IC351) provides prompt response and extended period of responsiveness for the treatment of men with erectile dysfunction (abstract). J Urol 2001;165(suppl):224.
61. Brock GB, McMahon CG, Chen KK, Costigan T, Shen W, Watkins V, et al. Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J Urol 2002;168:1332-6.
62. Porst H, Padma-Nathan H, Giuliano F, Anglin G, Varanese L, Rosen R. Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: a randomized controlled trial. Urology 2003;62:121-5.
63. Skoumal R, Chen J, Kula K, Breza J, Calomfirescu N, Basson BR, et al. Efficacy and treatment satisfaction with on-demand tadalafil (Cialis) in men with erectile dysfunction. Eur Urol 2004;46:362-9.
64. Montorsi F, Verheyden B, Meuleman E, Junemann KP, Moncada I, Valiquette L, et al. Long-term safety and tolerability of tadalafil in the treatment of erectile dysfunction. Eur Urol 2004;45:339-45.
65. Goldstein I, Young JM, Fischer J, Bangerter K, Segerson T, Taylor T; Vardenafil Study Group. Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: a multicenter double-blind placebo-controlled fixed-dose study. Diabetes Care 2003;26:777-83.
66. Saenz de Tejada I, Anglin C, Knight JR, Emmick JT. Effects of tadalafil on erectile dysfunction in men with diabetes. Diabetes Care 2002;25:2159-64.
67. Perimenis P, Markou S, Gyftopoulos K, Athanasopoulos A, Giannitsas K, Barbalias G. Switching from long-term treatment with self-injections to oral sildenafil in diabetic patients with severe erectile dysfunction. Eur Urol 2002;41:387-91.
68. Safarinejad MR. Oral sildenafil in the treatment of erectile dysfunction in diabetic men: a randomized double-blind and placebo-controlled study. J Diabetes Complications 2004;8:205-10.
69. Brock G. Taylor T, Seger M, for the Vardenafil PROSPECT Group. Efficacy and tolerability of Vardenafil in men with erectile dysfunction following radical prostatectomy (abstract). Eur Urol 2002;1:52.
70. Raina R, Lakin MM, Agarwal A, et al. Long-term effect of sildenafil citrate on erectile dysfunction after radical prostatectomy: 3-year follow-up. Urology 2003;62:110-5.
71. Raina R, Lakin MM, Agarwal A, Sharma R, Goyal KK, Montague DK, et al. Efficacy and factors associated with successful outcome of sildenafil citrate use for erectile dysfunction after radical prostatectomy. Urology 2004;63:960-6.
72. Raina R, Lakin MM, Agarwal A, Mascha E, Montague DK, Klein E, et al. Long-term intracavernous therapy responders can potentially switch to sildenafil citrate after radical prostatectomy. Urology 2004;63:532-7.
73. Zagaja GP, Mhoon DA, Aikens JE, Brendler CB. Sildenafil in the treatment of erectile dysfunction after radical prostatectomy. Urology 2000;56:631-4.
74. Zippe CD, Jhaveri FM, Klein EA, Kedia S, Pasqualotto FF, Kedia A, et al. Role of Viagra after radical prostatectomy. Urology 2000;55:241-5.
75. Montorsi F, Nathan HP, McCullough A, Brock GB, Broderick G, Ahuja S, et al. Tadalafil in the treatment of erectile dysfunction following bilateral nerve sparing radical retropubic prostatectomy: a randomized, double-blind, placebo controlled trial. J Urol 2004;172:1036-41.